80 related articles for article (PubMed ID: 16125525)
1. Angiotensin II-induced oxidative burst is fluvastatin sensitive in neutrophils of patients with hypercholesterolemia.
Seres I; Fóris G; Páll D; Kosztáczky B; Paragh G; Varga Z; Paragh G
Metabolism; 2005 Sep; 54(9):1147-54. PubMed ID: 16125525
[TBL] [Abstract][Full Text] [Related]
2. The association between angiotensin II-induced free radical generation and membrane fluidity in neutrophils of patients with metabolic syndrome.
Seres I; Fóris G; Varga Z; Kosztáczky B; Kassai A; Balogh Z; Fülöp P; Paragh G
J Membr Biol; 2006; 214(2):91-8. PubMed ID: 17546512
[TBL] [Abstract][Full Text] [Related]
3. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
4. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptides induced a pronounced and statin-sensitive dysregulation of mevalonate cycle in human monocytes of patients with hypercholesterolemia.
Kosztáczky B; Fóris G; Seres I; Balogh Z; Fülöp P; Koncsos P; Paragh G
Neuropeptides; 2006 Oct; 40(5):309-16. PubMed ID: 17049599
[TBL] [Abstract][Full Text] [Related]
6. Development and pharmacology of fluvastatin.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):11-5. PubMed ID: 19489169
[TBL] [Abstract][Full Text] [Related]
7. Fluvastatin and fluvastatin extended release: a clinical and safety profile.
Asberg A; Holdaas H
Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):641-52. PubMed ID: 15350166
[TBL] [Abstract][Full Text] [Related]
8. Effects of statins on experimental colitis in normocholesterolemic rats.
Jahovic N; Gedik N; Ercan F; Sirvanci S; Yüksel M; Sener G; Alican I
Scand J Gastroenterol; 2006 Aug; 41(8):954-62. PubMed ID: 16803694
[TBL] [Abstract][Full Text] [Related]
9. Rac2 GTPase activation by angiotensin II is modulated by Ca2+/calcineurin and mitogen-activated protein kinases in human neutrophils.
El Bekay R; Alba G; Reyes ME; Chacón P; Vega A; Martín-Nieto J; Jiménez J; Ramos E; Oliván J; Pintado E; Sobrino F
J Mol Endocrinol; 2007 Nov; 39(5):351-63. PubMed ID: 17975262
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on copper-induced hydroxyl radical generation in the rat heart.
Obata T
Toxicology; 2006 Jun; 223(3):175-80. PubMed ID: 16647179
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention.
Kowalski J; Barylski M; Banach M; Grycewicz J; Irzmański R; Pawlicki L
J Cardiovasc Pharmacol; 2006 Oct; 48(4):143-7. PubMed ID: 17086091
[TBL] [Abstract][Full Text] [Related]
12. Chronic fluvastatin treatment alters vascular contraction by inhibiting the Rho/Rho-kinase pathway.
Kansui Y; Fujii K; Goto K; Oniki H; Iida M
Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):673-8. PubMed ID: 16895538
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of peripheral blood cytotoxic T-cells under fluvastatin treatment in renal transplant recipients.
Barlage S; Hauser IA; Elbracht R; Abletshauser C; Schmieder RE; Weidinger G; Lackner KJ; Rothe G; Schmitz G
J Biol Regul Homeost Agents; 2005; 19(3-4):159-68. PubMed ID: 16602632
[TBL] [Abstract][Full Text] [Related]
14. Fluvastatin prevents glutamate-induced blood-brain-barrier disruption in vitro.
Kuhlmann CR; Gerigk M; Bender B; Closhen D; Lessmann V; Luhmann HJ
Life Sci; 2008 Jun; 82(25-26):1281-7. PubMed ID: 18534629
[TBL] [Abstract][Full Text] [Related]
15. Fluvastatin prevents oxidized low-density lipoprotein-induced injury of renal tubular epithelial cells by inhibiting the phosphatidylinositol 3-kinase/Akt-signaling pathway.
Chu G; Jia R; Yang D
J Nephrol; 2006; 19(3):286-95. PubMed ID: 16874687
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II-stimulated collagen production in cardiac fibroblasts is mediated by reactive oxygen species.
Lijnen P; Papparella I; Petrov V; Semplicini A; Fagard R
J Hypertens; 2006 Apr; 24(4):757-66. PubMed ID: 16531806
[TBL] [Abstract][Full Text] [Related]
17. Stimulatory effects of low-dose 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on hepatocyte growth factor-induced angiogenesis: involvement of p38 mitogen-activated protein kinase.
Uruno A; Sugawara A; Kudo M; Satoh F; Saito A; Ito S
Hypertens Res; 2008 Nov; 31(11):2085-96. PubMed ID: 19098381
[TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat.
Zhou R; Xu Q; Zheng P; Yan L; Zheng J; Dai G
Eur J Pharmacol; 2008 May; 586(1-3):244-50. PubMed ID: 18384769
[TBL] [Abstract][Full Text] [Related]
20. Effect of glycine on the release of reactive oxygen species in human neutrophils.
Giambelluca MS; Gende OA
Int Immunopharmacol; 2009 Jan; 9(1):32-7. PubMed ID: 18835373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
